Skip to Content
Stock Analyst Update

Signs of Life in 3M’s Portfolio; We Raise Our FVE

We raise our fair value estimate to $180 per share, from $166 previously. It is our hope that the company continues to deliver on growth once again and re-earn both its premium multiple and reputation as a reliable short-cycle business, whose stocks are best to buy in the early parts of the cycle.

Mentioned:

 

Wide-moat rated 3M (MMM) had a solid third quarter that we think the market failed to appreciate. While we were initially frustrated by the company’s inability to meet its guide in multiple quarters pre-COVID-19, we think the stock is finally making a turn. The company is running decently ahead of our prior revenue forecast, and well ahead of our prior earnings free cash flow forecast. We now expect $31.8 billion of sales in full-year 2020, adjusted EPS of $8.56, and free cash flow (cash flow from operations less capital expenditures) of $5.9 billion, even with an elevated free cash flow forecast. As a result, we raise our fair value estimate to $180 per share, from $166 previously (or about a 7% raise, net of time value of money impacts). It is our hope that the company continues to deliver on growth once again and re-earn both its premium multiple and reputation as a reliable short-cycle business, whose stocks are best to buy in the early parts of the cycle.

While we’ve been wrong before when calling an inflection, we believe COVID-19-related tailwinds in certain high-impact businesses like personal safety equipment, home care, home improvement, and to a lesser extent, separation and purification, can build a sliver of a margin of safety in the stock along with its 3.7% dividend yield. We also like the addition of Monish Patolawala. Our conversations with him give us confidence he can be a valuable partner to CEO Mike Roman. One thing that gave us confidence was his belief that 3M should commit to certain capital projects with greater focus (rather than, in our words, trying to be the end-all, be-all for every single customer).

 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Joshua Aguilar does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.